Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aerovate Therapeutics (AVTE)
NASDAQ:AVTE
RESEARCH TOOLSreports
Holding AVTE?
Track your performance easily
AVTE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.25 - $32.42
Previous Close$2.66
Volume62.75K
Average Volume (3M)782.87K
Market Cap
$76.37M
Enterprise Value-$11.10M
Total Cash (Recent Filing)$88.73M
Total Debt (Recent Filing)$540.00K
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Mar 26, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.00
Shares Outstanding28,874,513
10 Day Avg. Volume319,806
30 Day Avg. Volume782,872
Standard Deviation0.31
R-Squared0.02
Alpha0.00434
Financial Highlights & Ratios
Price to Book (P/B)0.95
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.12
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Aerovate Therapeutics News
PremiumCompany Announcements
Aerovate Therapeutics Reports Q3 Loss Amid Strategic Shift
PremiumCompany Announcements
Aerovate Therapeutics and Jade Biosciences Announce Strategic Merger
PremiumCompany Announcements
Aerovate Therapeutics Board Member Maha Katabi Resigns
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
AVTE FAQ
What was Aerovate Therapeutics’s price range in the past 12 months?
Aerovate Therapeutics lowest stock price was $1.25 and its highest was $32.41 in the past 12 months.
What is Aerovate Therapeutics’s market cap?
Currently, no data Available
When is Aerovate Therapeutics’s upcoming earnings report date?
Aerovate Therapeutics’s upcoming earnings report date is Mar 26, 2025 which is in 124 days.
How were Aerovate Therapeutics’s earnings last quarter?
Aerovate Therapeutics released its earnings results on Nov 11, 2024. The company reported -$0.563 earnings per share for the quarter, missing the consensus estimate of -$0.56 by -$0.003.
Is Aerovate Therapeutics overvalued?
According to Wall Street analysts Aerovate Therapeutics’s price is currently Overvalued.
Does Aerovate Therapeutics pay dividends?
Aerovate Therapeutics does not currently pay dividends.
What is Aerovate Therapeutics’s EPS estimate?
Aerovate Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aerovate Therapeutics have?
Aerovate Therapeutics has 28,874,514 shares outstanding.
What happened to Aerovate Therapeutics’s price movement after its last earnings report?
Aerovate Therapeutics reported an EPS of -$0.563 in its last earnings report, missing expectations of -$0.56. Following the earnings report the stock price went down -3.309%.
Which hedge fund is a major shareholder of Aerovate Therapeutics?
Among the largest hedge funds holding Aerovate Therapeutics’s share is RA Capital Management. It holds Aerovate Therapeutics’s shares valued at 19M.
---
Aerovate Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Hedge Fund Trend
Decreased
By 416.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 1.5%
Last 30 Days ▼ 1.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-81.66%
12-Months-Change
Fundamentals
Return on Equity
-82.06%
Trailing 12-Months
Asset Growth
-35.43%
Trailing 12-Months
Company Description
Aerovate Therapeutics
Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. Its initial focus is on advancing AV-101, dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, a devastating disease impacting people in the United States and Europe.
---
AVTE Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Best Analysts Covering AVTE
1 Year
1 Year Success Rate
0/2 ratings generated profit
1 Year Average Return
-86.55%
reiterated a buy rating 6 months ago
Copying Laura Chico's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -86.55% per trade.
---